CDKN2A and neoplasm: The most frequently altered gene was TP53 (64%, not considered actionable), followed by actionable target genes CDKN2A (6%, biallelically inactivated), PIK3CA (10%) and KRAS (8%), including two KRAS p.G12C variants which are now considered targetable in other tumor types.